Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL(R) (bempedoic acid) Prior to April 19, 2040
(NasdaqGM:ESPR), ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare Inc. in response to Accord Healthcare Inc's Abbreviated New Drug Application (ANDA) seeking approval to market […]